Breast cancer resources

The following list includes a sampling of specialized Web sites supported by AstraZeneca, as well as other organizations that offer education, support, and advocacy for women like you fighting breast cancer.

AstraZeneca resources
Other breast cancer resources

AstraZeneca resources

AstraZeneca is committed to the fight against breast cancer. The following resources are sponsored by AstraZeneca, including the official product Web sites. You'll find detailed information about each medication, as well as facts on breast cancer, treatments, support groups, resources, and insurance coverage.

ARIMIDEX.com — The official Web site for ARIMIDEX, a hormonal treatment (also called hormonal therapy) approved for postmenopausal women with hormone receptor-positive early breast cancer and for the initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. Provides complete details on how ARIMIDEX works, findings from the ATAC (ARIMIDEX, Tamoxifen, Alone or in Combination) clinical trial, the risk of breast cancer recurrence, maintaining breast health, and more.

FASLODEX.com
The official Web site for FASLODEX^® (fulvestrant) Injection, a hormonal treatment approved for hormone receptor-positive metastatic breast cancer in postmenopausal women whose disease has returned or progressed following antiestrogen therapy. Provides complete details for women with advanced disease on how FASLODEX works, the results of two major clinical research studies on this medication, a resource database, and more.

Other breast cancer resources

The following list of resources is provided merely as a convenience. AstraZeneca takes no responsibility for the content of, or services provided by, these resources, and makes no representations as to the accuracy or completeness of any information provided. AstraZeneca shall have no liability for any damages or injuries of any kind arising from the information provided.

breastcancer.org
This physician-founded organization offers information about treatment options and post-treatment care, 24-hour chat rooms, the latest research news, and more. It also offers occasional online conferences with breast cancer experts and images of different forms of breast cancer.

Breast Cancer Action
This site has information on how to take action to help put an end to the breast cancer epidemic. It also includes suggestions for women newly diagnosed with breast cancer as well as details pertaining to membership and support.

Living Beyond Breast Cancer
This organization provides current news about breast cancer and relevant clinical research studies through its Web site, patient networking conferences, and interactive teleconferences with experts on a myriad of breast cancer issues. The site also offers empowering stories about women living with breast cancer, as well as message boards.

Susan G. Komen For The Cure^®
This foundation is dedicated to eradicating breast cancer as a life-threatening disease through research, education, screening, and treatment. It raises awareness and funds for breast cancer research with its annual Susan G. Komen Race for the Cure events across the country. Services include a toll-free "helpline" (1-800-IM-AWARE) staffed by trained volunteers. The foundation also funds research and other cancer-related programs.

Breast Cancer Network of Strength™
This organization has 10 regional affiliates around the country and can provide more "localized" services. These include a 24-hour hotline staffed by counselors who are breast cancer survivors, a match program to pair patients with similar diagnoses, and monthly teleconferences with medical professionals followed by small group discussions with callers.

Important Information About ARIMIDEX

ARIMIDEX is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer.

ARIMIDEX is approved for the initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. Patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to ARIMIDEX.

Important Safety Information About ARIMIDEX

Prescription ARIMIDEX is only for postmenopausal women. ARIMIDEX should not be taken if you are pregnant because it may harm your unborn child
Based on information from a study in patients with early breast cancer, women with a history of blockages in heart arteries (ischemic heart disease) who take ARIMIDEX may have a slight increase in this type of heart disease compared to similar patients who take tamoxifen
ARIMIDEX can cause bone softening/weakening (osteoporosis) increasing the chance of fractures. In a clinical study in early breast cancer, there were more fractures (including fractures of the spine, hip, and wrist) with ARIMIDEX (10%) than with tamoxifen (7%)
In a clinical study in early breast cancer, some patients taking ARIMIDEX had an increase in cholesterol. Skin reactions, allergic reactions, and changes in blood tests of liver function have also been reported
In the early breast cancer clinical trial, the most common side effects seen with ARIMIDEX include hot flashes, joint symptoms (including arthritis and arthralgia), weakness, mood changes, pain, back pain, sore throat, nausea and vomiting, rash, depression, high blood pressure, osteoporosis, fractures, swelling of arms/legs, insomnia, and headache
In advanced breast cancer trials, the most common side effects seen with ARIMIDEX versus tamoxifen include hot flashes, nausea, decreased energy and weakness, pain, back pain, headache, bone pain, increased cough, shortness of breath, sore throat, and swelling of arms and legs. Joint pain/stiffness has been reported in association with the use of ARIMIDEX
ARIMIDEX should not be taken with tamoxifen or estrogen-containing therapies

Please see full Prescribing Information.

Important Information About FASLODEX Injection

FASLODEX is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women whose disease has returned or progressed following antiestrogen therapy.

Important Safety Information About FASLODEX

Prescription FASLODEX is only for postmenopausal women. Do not take FASLODEX if you are pregnant and do not become pregnant while taking FASLODEX, because it may harm your unborn child. (See warnings and contraindications sections of full Prescribing Information.)
Because FASLODEX is administered intramuscularly, it should not be used in patients with certain blood disorders or in patients receiving anticoagulants (sometimes called blood thinners, for example, warfarin)
In clinical studies, the most commonly reported side effects were nausea, vomiting, constipation, diarrhea, abdominal pain, headache, back pain, hot flashes, sore throat, and injection site reactions with mild, transient pain and inflammation

Please click here for full Prescribing Information.

For more information, see your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

This site is intended for US consumers.

ARIMIDEX and FASLODEX are registered trademarks of the AstraZeneca group of companies. All other registered trademarks are the property of their respective owners.